Rare disease companies bringing a new therapy to market face a distinct medical education challenge: awareness of the disease itself may still be limited. Healthcare professionals may encounter only a small number of affected patients, symptoms can overlap with more common conditions, and diagnosis may depend on recognising when specialist referral or further testing is needed. A multinational survey of 978 clinicians found substantial gaps in rare-disease knowledge and confidence, including barriers related to signs and symptoms, testing and referral.

This makes launch education more than a communication task. If the relevant HCPs do not recognise the disease, understand the diagnostic pathway or know when specialist evaluation is appropriate, new clinical evidence may not reach the people who need it in a clinically meaningful way. For rare disease companies, the educational challenge therefore starts with the disease and patient pathway – not only with the product.

This is where Billev Pharma East can help. Through our medical education services, we support teams searching for affordable med ed partners for rare disease product launches by developing focused scientific and educational activities that translate complex rare-disease evidence into relevant education for the HCPs involved in recognition, diagnosis, referral and patient management.

What should rare disease companies map before launch education begins?

Before developing content or selecting formats, rare disease companies should map where education is needed along the disease pathway. The priority is to understand which HCPs are likely to first encounter the patient, who confirms the diagnosis, where referral decisions occur and which specialists are responsible for ongoing management.

This is especially important in rare diseases because the educational need is rarely the same across the pathway. Evidence from rare-disease research shows that awareness and information needs can differ substantially between general practitioners  and specialists, with red flags, diagnostic testing and referral among recurring areas of need.

The company should therefore establish the key HCP audiences, the most important clinical questions, the available evidence, the launch stage and the markets in scope. Existing educational materials should also be reviewed so that new work addresses a genuine gap rather than reproducing information that already exists.

The programme does not need to be fully designed before external support is involved. A clear picture of the disease pathway, educational need and launch objective is enough to create a strong starting point for focused medical education consulting and the development of a relevant medical education programme.

How can Billev Pharma East support rare disease companies with medical education?

For rare disease companies, the difficult part is often turning a complex disease story into education that is useful to very different HCP audiences. Billev Pharma East helps bridge that gap by connecting the clinical evidence, the patient and referral pathway, and the practical educational need around the launch.

Our medical education services can support disease-awareness education, scientific and medical content, expert engagement, educational meetings, webinars and other HCP-focused activities. Because our Medical Affairs work is supported by medical writing, regulatory affairs, pharmacovigilance and medical consultancy expertise, we can develop education with the wider scientific and compliance context in mind. Billev Pharma East also supports patient journey strategy, which is particularly relevant when diagnosis and referral pathways are central to the educational challenge.

The support can be sized around the actual launch need. A company may require one highly focused educational initiative, access to a medical education specialist for a specific scientific challenge, a sequence of activities for several HCP groups, or broader support as the programme develops. The objective is not to add unnecessary layers, but to give the internal team the scientific and operational support needed to move the programme forward.

What matters when planning affordable medical education for a rare disease product launch?

For teams evaluating affordable med ed partners for rare disease product launches, affordability should mean a programme that is proportionate to the educational need – not a reduction in scientific quality. Rare-disease audiences may be smaller than in common conditions, but the content often needs to be more specialised and more precisely matched to the role each HCP plays.

The first priority is relevance. Education should address the clinical questions that matter most at that stage of the pathway, such as recognising disease signals, understanding diagnostic steps, knowing when referral is appropriate or interpreting emerging scientific evidence. The second priority is precision: specialists, referring physicians and other HCPs should not automatically receive the same depth of information or the same format.

Cost-efficiency comes from concentrating effort where it creates educational value. A focused medical education service can help build a strong scientific foundation that is then adapted across appropriate formats and audiences, while unnecessary duplication and overly broad activity are avoided. For rare disease companies, this creates a programme that remains scientifically robust but is still right-sized to the launch stage, HCP population and available resources.

Which medical education activities add the most value before a rare disease product launch?

The most valuable pre-launch activity is usually the one that addresses a defined knowledge or practice gap. In rare diseases, this may mean helping HCPs recognise relevant clinical signals, understand the diagnostic pathway, identify appropriate testing or know when specialist referral should be considered. Research in rare-disease education has repeatedly highlighted the importance of practical, clinically relevant information and professional training.

The activity should follow the role of the audience. A referring physician may benefit most from concise disease-awareness, red-flag and referral education, while a specialist may need deeper scientific discussion of disease mechanisms, diagnostic criteria, management or emerging evidence. The format should serve the objective rather than drive it.

Timing also matters. Medical Affairs guidance for rare-disease product launches places disease and diagnosis education, scientific communication planning and HCP engagement across the pre-launch period rather than treating education as a launch-day activity. For rare disease companies, this supports a more deliberate sequence: build the disease foundation first, then increase scientific depth as the launch approaches.

How should medical education be adapted to different HCP audiences?

One educational message rarely works equally well for every HCP involved in a rare-disease pathway. Clinicians who may first encounter an undiagnosed patient need practical information that supports recognition, investigation and referral. Specialist audiences may require a much deeper discussion of pathophysiology, diagnostic criteria, clinical evidence and disease management.

The delivery format should also reflect the learning need. In the multinational clinician survey, respondents showed strong interest in current, practical and case-based resources, including short formats that can be accessed efficiently. A 2026 scoping review likewise found that professional education and training were the most frequently identified recommendation across the rare-disease education literature.

For rare disease companies, this means designing education around clinical roles and decisions rather than simply repurposing the same content for every audience. The result is more relevant education and a more efficient use of launch resources.

When should rare disease companies involve a medical education partner?

External support is most useful when it is involved early enough to shape how the science is translated into education, rather than only after individual materials have already been defined. A practical point to involve a partner is when the main HCP audiences and educational gaps are becoming clear but the programme is still being developed.

At this stage, disease awareness, diagnostic and referral needs, emerging evidence and audience-specific education can still be connected into one coherent plan. Rare-disease Medical Affairs guidance similarly places scientific platform development, communication planning, HCP insight generation and disease and diagnosis education across the pre-launch period.

For rare disease companies, external support can become particularly valuable when several activities need to move forward at the same time or when the programme expands across audiences, formats or markets. Bringing in medical education expertise at this point can reduce fragmentation and make later launch activities easier to develop and adapt.

Why choose Billev Pharma East for rare disease medical education?

Rare-disease product launches need medical education that is focused enough for a small, specialised audience but strong enough to address complex disease, diagnostic and referral questions. Billev Pharma East brings together Medical Affairs, scientific content development, medical writing, patient journey expertise, regulatory affairs and pharmacovigilance to support that need.

For rare disease companies preparing for launch, this means access to a multidisciplinary team that can support the programme at the level actually required – from a focused educational initiative to broader launch support.

Frequently asked questions

Sources: 1 – Rohani-Montez, S. C., Bomberger, J., Zhang, C., Cohen, J., McKay, L., & Evans, W. R. H. (2023). Educational needs in diagnosing rare diseases: A multinational, multispecialty clinician survey. Genetics in Medicine Open, 1(1), 100808, 2 – Yamada, D. B., Komoto, T. T., Lima, V. C., Souza, J., Seixas, M. S., Cassão, V., Ferraz, V. E. F., de Oliveira, B. M., Félix, T. M., & Alves, D. (2026). Main Recommendations for Developing Education and Awareness Strategies for Rare Diseases: Scoping Review. JMIR Medical Education, 12, e79027, 3 – Medical Affairs Professional Society (MAPS). (2022). Medical Affairs Strategy for the Launch of Innovative Treatments Targeting Rare Disease. Medical Affairs Professional Society, 4 – Vandeborne, L., van Overbeeke, E., Dooms, M., De Beleyr, B., & Huys, I. (2019). Information needs of physicians regarding the diagnosis of rare diseases: A questionnaire-based study in Belgium. Orphanet Journal of Rare Diseases, 14.